热消融治疗孤立性T1bN0M0甲状腺乳头状癌的多中心疗效与安全性研究
本研究回顾性分析12家医院172例接受热消融的孤立性T1bN0M0甲状腺乳头状癌患者,随访24.9±14.1个月。消融后各时间点肿瘤最大径和体积均显著小于消融前,61.6%肿瘤完全消失,淋巴结转移率0.6%,并发症率5.2%。热消融对不适合或不愿手术的此类患者可能是一种可行、有效且安全的选择。
要点
- 热消融后6至48个月肿瘤最大径和体积均显著小于消融前。
- 末次随访61.6%肿瘤完全消失,淋巴结转移率0.6%。
- 总并发症率5.2%,主要并发症均于消融后4个月内缓解。
核心结论
- 热消融对不适合或不愿手术的孤立性T1bN0M0甲状腺乳头状癌患者可能是可行、有效且安全的治疗选择。
研究设计与样本
- 回顾性多中心研究,纳入2015年4月至2020年3月12家医院172例(男38例,女134例)接受热消融治疗的孤立性T1bN0M0甲状腺乳头状癌患者。
- 平均随访时间24.9±14.1个月(范围12-60个月)。
主要发现
- 所有患者均接受扩大消融,消融后超声造影确认。
- 消融后6、12、18、24、36、48个月消融区最大径和体积均显著小于消融前(P<0.05)。
- 末次随访时106例(61.6%)肿瘤完全消失。
- 淋巴结转移率0.6%(1/172),新发肿瘤发生率1.2%(2/172)。
- 总并发症率5.2%(9/172),主要并发症4.6%(8/172),次要并发症0.6%(1/172),所有主要并发症在消融后4个月内缓解。
临床怎么用
- 对于不适合或不愿手术的孤立性T1bN0M0甲状腺乳头状癌患者,热消融可作为备选治疗方案之一。
- 治疗后需通过超声造影评估消融范围,并定期随访监测肿瘤大小、淋巴结转移及新发肿瘤。
局限性
- 本研究为回顾性分析,随访时间相对较短(平均24.9个月),远期疗效需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ultrasound-guided thermal ablation plays an important role in the management of thyroid disease. The objective of this study was to evaluate the feasibility, efficacy, and safety of thermal ablation for patients with solitary T1bN0M0 papillary thyroid carcinoma (PTC) who are ineligible for or unwilling to undergo surgery. MATERIALS AND METHODS: Data pertaining to 172 patients (38 males and 134 females) who received thermal ablation therapy at 12 hospitals between April 2015 and March 2020 were retrospectively analyzed. The mean duration of follow-up was 24.9 ± 14.1 months (range, 12-60). The technical feasibility, technical success, efficacy, and safety of treatment were analyzed. Postablation tumor size at various time points was compared with preablation measurement. RESULTS: All patients selected for thermal ablation received enlarged ablation, according to contrast-enhanced ultrasound postablation. The maximum diameter and volume of ablation zone at 6, 12, 18, 24, 36, and 48 months postablation were significantly smaller than those recorded preablation (P < 0.05 for all). At the most recent follow-up, 106 (61.6%) tumors had completely disappeared. The rate of lymph node metastasis was 0.6% (1/172) and the incidence of new tumors was 1.2% (2/172). The overall complication rate was 5.2% (9/172) (major complications: 4.6% [8/172]; minor complications: 0.6% [1/172]). All major complications were relieved within 4 months postablation. CONCLUSION: Thermal ablation may be a feasible, effective, and safe treatment option for patients with solitary T1bN0M0 PTC who are ineligible for or unwilling to undergo surgery. It may provide a novel treatment option for selected patients.
引用
- Cao XJ, Liu J, Zhu YL, et al. Efficacy and Safety of Thermal Ablation for Solitary T1bN0M0 Papillary Thyroid Carcinoma: A Multicenter Study. J Clin Endocrinol Metab. 2021. PMID: 33107573. doi:10.1210/clinem/dgaa776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。